BR112017015206B1 - Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos - Google Patents

Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos Download PDF

Info

Publication number
BR112017015206B1
BR112017015206B1 BR112017015206-1A BR112017015206A BR112017015206B1 BR 112017015206 B1 BR112017015206 B1 BR 112017015206B1 BR 112017015206 A BR112017015206 A BR 112017015206A BR 112017015206 B1 BR112017015206 B1 BR 112017015206B1
Authority
BR
Brazil
Prior art keywords
compound
formula
ibrutinib
scheme
acid
Prior art date
Application number
BR112017015206-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017015206A2 (pt
Inventor
Cyril Benhaim
Wei Chen
Erick Goldman
Andras Horvath
Philip Pye
Mark S. Smyth
Erik J. Verner
Original Assignee
Pharmacyclics Llc
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc, Janssen Pharmaceutica Nv filed Critical Pharmacyclics Llc
Publication of BR112017015206A2 publication Critical patent/BR112017015206A2/pt
Publication of BR112017015206B1 publication Critical patent/BR112017015206B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017015206-1A 2015-01-14 2016-01-14 Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos BR112017015206B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
BR112017015206A2 BR112017015206A2 (pt) 2018-06-19
BR112017015206B1 true BR112017015206B1 (pt) 2023-04-11

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015206-1A BR112017015206B1 (pt) 2015-01-14 2016-01-14 Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos

Country Status (16)

Country Link
US (6) US20180009814A1 (https=)
EP (1) EP3245208A4 (https=)
JP (2) JP2018502077A (https=)
KR (1) KR20170102887A (https=)
CN (2) CN113816962A (https=)
AU (2) AU2016206693A1 (https=)
BR (1) BR112017015206B1 (https=)
CA (2) CA3210320A1 (https=)
HK (1) HK1246293A1 (https=)
IL (4) IL308276A (https=)
MA (1) MA41350A (https=)
MX (2) MX366827B (https=)
RU (1) RU2017128308A (https=)
SG (2) SG10201906517VA (https=)
WO (1) WO2016115356A1 (https=)
ZA (1) ZA201704338B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214532B2 (en) * 2015-02-12 2019-02-26 Shanghai Dude Medical Science and Technology Co., Ltd. Process for preparing ibrutinib
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
AU2020278162A1 (en) 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
WO2022157250A1 (en) 2021-01-21 2022-07-28 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
BRPI0418078A8 (pt) * 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Also Published As

Publication number Publication date
WO2016115356A1 (en) 2016-07-21
US20200347064A1 (en) 2020-11-05
MA41350A (fr) 2017-11-21
CN113816962A (zh) 2021-12-21
IL253020A0 (en) 2017-08-31
US20240158400A1 (en) 2024-05-16
ZA201704338B (en) 2023-10-25
SG11201705678YA (en) 2017-08-30
RU2017128308A (ru) 2019-02-14
BR112017015206A2 (pt) 2018-06-19
HK1246293A1 (zh) 2018-09-07
IL274716A (en) 2020-07-30
KR20170102887A (ko) 2017-09-12
CA3210320A1 (en) 2016-07-21
IL308276A (en) 2024-01-01
RU2017128308A3 (https=) 2019-10-24
AU2020230323A1 (en) 2020-10-01
AU2016206693A1 (en) 2017-07-13
EP3245208A1 (en) 2017-11-22
MX2019008815A (es) 2019-09-26
MX394327B (es) 2025-03-24
EP3245208A4 (en) 2018-10-17
SG10201906517VA (en) 2019-08-27
US20250197404A1 (en) 2025-06-19
JP2018502077A (ja) 2018-01-25
MX366827B (es) 2019-07-25
MX2017009154A (es) 2017-10-12
JP2021035947A (ja) 2021-03-04
CN107108640A (zh) 2017-08-29
US20190367518A1 (en) 2019-12-05
US20220098200A1 (en) 2022-03-31
CA2971460C (en) 2023-10-10
US20180009814A1 (en) 2018-01-11
CA2971460A1 (en) 2016-07-21
IL322449A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
BR112017015206B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos
TWI658042B (zh) 雜環化合物的合成
AU2017256626B2 (en) Synthesis of indazoles
CA2934537C (en) Synthesis of an antiviral compound
CN104114542B (zh) 三唑并嘧啶化合物的合成
AU2017256659B2 (en) Synthesis of indazoles
RS62254B1 (sr) Derivati pirimidina za tretman virusnih infekcija
EP2415744A1 (en) Fluorene compound
BR122017005939A2 (pt) processo para a fabricação de derivados de sulfamida pirimidina
CN112585126B (zh) 四环化合物的制备方法
JP2008540414A (ja) 場合により２−置換されていてもよい１，６−ジヒドロ−６−オキソ−４−ピリミジンカルボン酸の製造方法
JP6411371B2 (ja) 殺線虫性スルホンアミドの調製
CN107513050B (zh) 一种烯酸溴内酯化的制备方法
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
WO2017162204A1 (zh) 苯并呋喃类似物制备方法及其中间体和晶型
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
CN101279974A (zh) 吡唑并嘧啶酮衍生物及其制备方法和应用
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
JP7665386B2 (ja) デオキシハロゲノグルコン酸誘導体及びその製造方法、並びに、デオキシスルホニルオキシグルコン酸誘導体及びその製造方法
TWI389912B (zh) 用於製備ｎ－〔５－（３－二甲胺基－丙烯醯基）－２－氟苯基〕－ｎ－甲基－乙醯胺之方法
KR20200092945A (ko) 레날리도마이드의 결정형
CN107771179A (zh) 氨基磷酸酯的合成
RU2575174C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 5,6-ДИГИДРОПИРРОЛО[2,1-a]ИЗОХИНОЛИНОВ, СОДЕРЖАЩИХ В ПОЛОЖЕНИИ 2 ФУНКЦИОНАЛЬНУЮ ГРУППУ
CN111410650A (zh) 制备磺胺类药物的方法
BR112019019686B1 (pt) Compostos selecionados para síntese de inibidor de mcl-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04

Ipc: C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61P

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026564-2 PROTOCOLO 870220121728 EM 23/12/2022 17:40.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2016, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: PHARMACYCLICS LLC (US) ; JANSSEN PHARMACEUTICA NV (BE)